Euroscreen S.A.

Euroscreen's research activities began with the process of 'de-orphanizing' G protein-coupled receptors (GPCRs). This has been an important source of new targets for the development of our drug discovery programs and aspects of our patent portfolio.

We have most of the orphan human GPCRs cloned and expressed in cell lines suitable for functional testing. These cell lines are available for custom screening.

Euroscreen has one of the best, scientific track records of any biopharmaceutical company today for deorphanizing GPCRs.

Our expertise combines our in-house R&D, equipment and technologies to drive our research for these new targets (see Target Discovery Activities).